Literature DB >> 14596938

The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.

Steven W Paugh1, Shawn G Payne, Suzanne E Barbour, Sheldon Milstien, Sarah Spiegel.   

Abstract

The potent immunosuppressive drug FTY720, a sphingosine analog, induces redistribution of lymphocytes from circulation to secondary lymphoid tissues. FTY720 is phosphorylated in vivo and functions as an agonist for four G-protein-coupled sphingosine-1-phosphate receptors. The identity of the kinase that phosphorylates FTY720 is still not known. Here we report that although both sphingosine kinase type 1 (SphK1) and type 2 (SphK2) can phosphorylate FTY720 with low efficiency, SphK2 is much more effective than SphK1. FTY720 inhibited phosphorylation of sphingosine catalyzed by SphK2 to a greater extent than it inhibits SphK1. Thus, SphK2 may be the relevant enzyme that is responsible for in vivo phosphorylation of FTY720.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14596938     DOI: 10.1016/s0014-5793(03)01168-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  104 in total

1.  Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling.

Authors:  Christina D Keller; Pilar Rivera Gil; Markus Tölle; Markus van der Giet; Jerold Chun; Heinfried H Radeke; Monika Schäfer-Korting; Burkhard Kleuser
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

2.  Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient.

Authors:  Krishnan Venkataraman; Shobha Thangada; Jason Michaud; Myat Lin Oo; Youxi Ai; Yong-Moon Lee; Mingtao Wu; Nehal S Parikh; Faraz Khan; Richard L Proia; Timothy Hla
Journal:  Biochem J       Date:  2006-08-01       Impact factor: 3.857

3.  FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.

Authors:  Qing Liu; Xiaobin Zhao; Frank Frissora; Yihui Ma; Ramasamy Santhanam; David Jarjoura; Amy Lehman; Danilo Perrotti; Ching-Shih Chen; James T Dalton; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2007-08-29       Impact factor: 22.113

4.  B lymphocytes exit lymph nodes through cortical lymphatic sinusoids by a mechanism independent of sphingosine-1-phosphate-mediated chemotaxis.

Authors:  Rajesh K Sinha; Chung Park; Il-Young Hwang; Michael D Davis; John H Kehrl
Journal:  Immunity       Date:  2009-02-19       Impact factor: 31.745

5.  Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells.

Authors:  Barbara S Paugh; Lauren Bryan; Steven W Paugh; Katarzyna M Wilczynska; Silvina M Alvarez; Sandeep K Singh; Dmitri Kapitonov; Hanna Rokita; Sarah Wright; Irene Griswold-Prenner; Sheldon Milstien; Sarah Spiegel; Tomasz Kordula
Journal:  J Biol Chem       Date:  2008-12-11       Impact factor: 5.157

Review 6.  Sphingosine-1-phosphate in chronic intestinal inflammation and cancer.

Authors:  Masayuki Nagahashi; Nitai C Hait; Michael Maceyka; Dorit Avni; Kazuaki Takabe; Sheldon Milstien; Sarah Spiegel
Journal:  Adv Biol Regul       Date:  2013-10-16

7.  Deactivation of sphingosine kinase 1 by protein phosphatase 2A.

Authors:  Renae K Barr; Helen E Lynn; Paul A B Moretti; Yeesim Khew-Goodall; Stuart M Pitson
Journal:  J Biol Chem       Date:  2008-10-13       Impact factor: 5.157

8.  Fingolimod Suppresses the Proinflammatory Status of Interferon-γ-Activated Cultured Rat Astrocytes.

Authors:  Saša Trkov Bobnar; Matjaž Stenovec; Katarina Miš; Sergej Pirkmajer; Robert Zorec
Journal:  Mol Neurobiol       Date:  2019-01-30       Impact factor: 5.590

Review 9.  The role of sphingosine-1-phosphate and its receptors in asthma.

Authors:  John J Ryan; Sarah Spiegel
Journal:  Drug News Perspect       Date:  2008-03

Review 10.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.